Shares of Dr Reddy's Laboratories soared 10 percent to hit a record high of Rs 5,302.85 after the pharma company informed the settlement of their litigation with Celgene, a wholly-owned subsidiary of Bristol Myers Squibb, relating to patents for REVLIM (lenalidomide) capsules.
"In settlement of all outstanding claims in the litigation, Celgene has agreed to provide Dr Reddy's with license to sell volume-limited amounts of generic lenalidomodie capsules in the U.S. beginning on a confidential date after March 2022 subject to regulatory approval," the company said in a stock exchange filing.
It added that the agreed-upon percentages are confidential.
"Dr. Reddy's is also licensed to sell generic lenalidomide capsules in the U.S. without volume limitation beginning on January 31, 2026," it said.
Notifications
Settings
Clear Notifications
No New Notifications
Notifications
Use the toggle to switch on notifications
Block for 8 hours
Block for 12 hours
Block for 24 hours
Don't block
To start receiving timely alerts, as shown below click on the Green “lock” icon next to the address bar
Click it and Unblock the Notifications
Close X
Close X
To Start receiving timely alerts please follow the below steps:
Click on the Menu icon of the browser, it opens up a list of options.
Click on the “Options ”, it opens up the settings page,
Here click on the “Privacy & Security” options listed on the left hand side of the page.
Scroll down the page to the “Permission” section .
Here click on the “Settings” tab of the Notification option.
A pop up will open with all listed sites, select the option “ALLOW“, for the respective site under the status head to allow the notification.
Once the changes is done, click on the “Save Changes” option to save the changes.
Click it and Unblock the Notifications
Sign in with Google